Publicaciones en colaboración con investigadores/as de University of Michigan–Ann Arbor (24)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

  2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  3. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts

    BLOOD CANCER DISCOVERY, Vol. 3, Núm. 6

2021

  1. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

    Hepatology Communications, Vol. 5, Núm. 3, pp. 538-547

  2. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2019

  1. Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0

    Nature Protocols, Vol. 14, Núm. 3, pp. 639-702

2017

  1. BCL6 antagonizes NOTCH2 to maintain survival of human follicular lymphoma cells

    Cancer Discovery, Vol. 7, Núm. 5, pp. 506-521

2016

  1. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

    Cell, Vol. 166, Núm. 4, pp. 963-976

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  2. The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling

    Journal of Biological Chemistry, Vol. 289, Núm. 40, pp. 27727-27743

2013

  1. A novel fatty acid lipophilic index and risk of CHD in US men: The Health Professionals Follow-Up Study

    British Journal of Nutrition, Vol. 110, Núm. 3, pp. 466-474

  2. A novel fatty acid profile index-the lipophilic index-and risk of myocardial infarction

    American Journal of Epidemiology, Vol. 178, Núm. 3, pp. 392-400

  3. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC

    Leukemia, Vol. 27, Núm. 3, pp. 686-694

2010

  1. Ki67: A time-varying biomarker of risk of breast cancer in atypical hyperplasia

    Breast Cancer Research and Treatment, Vol. 121, Núm. 2, pp. 431-437